Unknown

Dataset Information

0

Immune checkpoint inhibitors for small cell lung cancer: opportunities and challenges.


ABSTRACT: Lung cancer is the most common cancer and the leading cause of cancer death worldwide, with an estimated 2.1 million new cases and 1.8 million deaths in 2018. Although small cell lung cancer (SCLC) is the most aggressive type of lung cancer, it shows high response rates to chemotherapy in early lines of therapy. Unfortunately, it is associated with rapid recurrence and relatively poor prognosis. Over the last few years, considerable progress has been made in cancer immunotherapy. One of the most promising ways to activate therapeutic antitumor immunity is via blockade of immune checkpoints, such as cytotoxic T lymphocyte-associated protein-4 (CTLA-4) and programmed cell death protein-1/programmed cell death ligand-1 (PD-1/PD-L1). Immune checkpoint inhibitors show promise as SCLC therapeutics. The overall expectation for immuno-oncology is high, and the outcomes of trials will hopefully reveal a variety of treatment options for SCLC patients. In this review, we discuss the discovery of new immune inhibitory and stimulatory pathways and rational combination strategies to explain the role of immunotherapy in SCLC and its future opportunities and challenges.

SUBMITTER: Regzedmaa O 

PROVIDER: S-EPMC6580132 | biostudies-literature | 2019

REPOSITORIES: biostudies-literature

altmetric image

Publications

Immune checkpoint inhibitors for small cell lung cancer: opportunities and challenges.

Regzedmaa Orgilmaa O   Zhang Hongbing H   Liu Hongyu H   Chen Jun J  

OncoTargets and therapy 20190613


Lung cancer is the most common cancer and the leading cause of cancer death worldwide, with an estimated 2.1 million new cases and 1.8 million deaths in 2018. Although small cell lung cancer (SCLC) is the most aggressive type of lung cancer, it shows high response rates to chemotherapy in early lines of therapy. Unfortunately, it is associated with rapid recurrence and relatively poor prognosis. Over the last few years, considerable progress has been made in cancer immunotherapy. One of the most  ...[more]

Similar Datasets

| S-EPMC5313266 | biostudies-literature
| S-EPMC8267255 | biostudies-literature
| S-EPMC5994505 | biostudies-literature
| S-EPMC6394775 | biostudies-literature
| S-EPMC4993420 | biostudies-other
| S-EPMC6136858 | biostudies-other
| S-EPMC10242320 | biostudies-literature
| S-EPMC8913284 | biostudies-literature
| S-EPMC8391213 | biostudies-literature
| S-EPMC9345799 | biostudies-literature